AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

NextFerm Technologies Ltd.

Investor Presentation Aug 18, 2022

6948_rns_2022-08-18_52f0ce5b-acd9-45d0-8bc0-1a95f4ecd690.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

NEXTFERM TECHNOLOGIES

Leading The Alternative Protein Revolution

August 2022

DISCLAIMER

This presentation is intended for the provision of non-comprehensive information for the sake of convenience solely. You are hereby referred to the full prospectus and immediate and periodic reports filed by the company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. for information regarding the Company's activities and the risks entailed thereby, including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, that is included therein. In case of any discrepancy between the information contained herein and the information contained in the official reports of the Company to the Israeli Securities Authority and the Tel Aviv Stock Exchange, the information recorded in such reports shall prevail.

This presentation may include forward-looking statements and forward- looking information, including, but not limited to developments, outlooks, projected economy measures, etc.. Such forward-looking statements and information are based on the current assumptions, intentions and plans of the Company. The forward-looking information in the presentation is subject to risks and uncertainties and may not materialize, in whole or in part, or may materialize significantly differently than as predicted, or may be affected by various factors, including factors that are not under the Company's control or such that cannot be estimated in advance. The Company makes no representation or warranty of any kind with respect to such information.

For the avoidance of doubt, it is clarified that the Company does not undertake to update and/or modify the information included in this presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation does not constitute an offer, invitation or recommendation to purchase, sell, subscribe for or do any transactions in the securities of the Company, in any jurisdiction, and the information provided in this presentation is not a basis for the making of any investment decision, nor a recommendation or opinion, nor a substitute for the discretion and independent analysis of any potential investor.

This presentation includes information from public sources, which was not independently examined by the Company and the Company is not liable as to its accuracy.

ABOUT NEXTFERM: LEADING THE ALTERNATIVE PROTEIN REVOLUTION

Experienced Team in the Food and Food-tech Industry

Breakthrough Technology for Innovative Yeast-based Proteins and Nutrients

ProteVin™ Revolutionary Vegan Protein Launched in June 2022 (USA)

  • Yeast Derived
  • Animal-like Nutritional Value
  • Neutral Flavor (unlike typical plants-based proteins)

Additional commercial Stage Products

Significant Revenue and Profit Potential

ABOUT NEXTFERM – THE TEAM

Experienced Team in the Food and Food-tech Industries

Company management is comprised of former Senior Management of Enzymotec, which developed innovative ingredients within the world of nutrition. Enzymotec reached revenues of over \$80M and went public (NASDAQ) during 2013, with a market cap of \$300M

WORKING TOGETHER FOR OVER 15 YEARS

Yossi Ohana, CFO Former VP Finance of Enzymotec

Boaz Noy, CEO and Director

Former Sr. VP and Head of the BioActive Ingredients Division at Enzymotec

Yossi Peled, Chairman

Former Chairman and board member of Enzymotec and Former CEO of Galam

Yoni Twito, COO Former COO of Enzymotec

Arkadiy Haikin, VP of Engineering Former Chief of Engineering of Enzymotec

Gai Ben Dror, VP R&D & Process Development Former VP of Process Development of Enzymotec

Elzaphan Hotam CEO of NextFerm USA Former CEO of Enzymotec USA

ABOUT NEXTFERM – COMMERCIALIZED PRODUCTS

ProteVin™: Vegan protein with an animal-like nutritional value and neutral flavor

Launched in US during June 2022

AstaFerm®: Novel & Powerful Astaxanthin Antioxidant

NextFreeze™ and Biofuel: 2 yeast strains Licensed to Lallemand Inc., a global corporate specializing in yeast and bacteria. Included \$2.75M down payment

NextFreeze™ Biofuel

ABOUT NEXTFERM - TECHNLOGY

7

Breakthrough Technology

For producing yeast-derived, innovative, functional vegan food ingredients, based on:

  • Non-GMO Strain Improvement
  • Fermentation Expertise
  • Separation and Purification Techniques
  • Proven Scale-up Capabilities

BREAKTHROUGH TECHNOLOGY

Yeast Improvement (Patented, Non-GMO)

Improvement of yeast characteristics for either elevated expression of specific metabolites, stress resistance, and yield

Fermentation (Cost-effective)

Process optimization for economical production of the improved strain biomass

Separation & Purification

Development of efficient purification process for obtaining the desired ingredients applicable to food or dietary supplement

Scale-up (from Lab to Industry)

Implementation of the fermentation and purification processes to full production scale

The only fermented vegan protein with animal like nutritional value and neutral taste

WHY VEGAN PROTEIN

THE WORLD GOES VEGAN DUE TO THREE REASONS:

Health Plant based diet is healthier

Compassion Decrease animal suffering

Sustainability

Securing world natural resources

The growing shift towards vegan nutrition creates an increase in the need for vegan protein sources with better nutritional value that will enable consumers to enjoy vegan nutrition without compromising the joy of food

https://www.un.org/development/desa/en/news/population/world-population-prospects-2019.html

ALTERNATIVE FINISHED PRODUCTS MARKET IS EXPECTED TO GROW TO \$290B TILL 2035 (*)

An Analysis by BCG and Blue Horizon :

"Every Tenth Portion of Meat, Eggs, Dairy, and Seafood Eaten Around the Globe Will Be Made from Alternative Proteins by 2035"

Expected alternative market growth

Will Lead The BOOMING

Vegan Protein Market

PROTEVIN™- DISRUPTIVE VALUE PROPOSITION

YEAST DERIVED NON-GMO VEGAN PROTEIN PRODUCED THROUGH INNOVATIVE FERMENTATION PROCESSES

Animal-like nutritional value:

  • High level of Essential Amino Acids (53% EAA), Branched Amino Acids (21% BCAA) and 9% Leucine
  • Highly digestible protein (PDCAST=1)

Neutral flavor and taste: unlike other typical plant-based proteins or other yeast-based proteins

  • Optimal integration in food
  • Highly sustainable
  • No allergens or impurities
  • Regulatory status: Approved for marketing in the USA, EU & more
  • Competitive pricing

The leading alternative protein

Protein Source ProteVin™ Whey Soy Pea & Rice
Blend
Vegan Source + - + +
Allergen Free /
No impurities
+ - - -
Sustainability + - + +
Taste & Flavor + + - -
Amino Acid
Composition (AA)
+ + - -
High Digestibility + + + -

PROTEVIN™

Main evaluation responds from food and dietary supplement companies, who are examining the integration of ProteVin™ in a variety of alternative products

PROTEVIN™: OPERATIONAL PLAN

Initial production setup Commercial Launch

Initial Set-up of production by subcontractor (GFR Canada) capacity of 10s tons in 2022

Commercial launch and initial supply to a US customer (June 2022)

A 4.5 years supply agreement totaling approximately \$3M with Spacemilk

ProteVin™ is being tested by dozens of food and dietary supplement companies

Growth 1

Expansion of capacity to 100s tons/year expected to start during H2-2022

Towards industrial profitable production in 2023, with the ability to grow

PROTEVINKEY GOALS

FOR 2022 Operation of first manufacturing facility: With a capacity of tens of tons for 2022, GFR Canada (H1-2022).

Launch in USA: Starting supplying first orders (H1-2022).

Growing market demands: Additional orders, accelerating growth into sports nutrition and food markets by dominant players.

Expansion of production capacity: Reaching industrial and profitable scale of hundreds of tons per year will start during H2-2022. Industrial production planned for 2023, with the ability to grow.

Regulatory approval in Israel: Israel is the world's leading country in the transition to vegan nutrition and alternative nutrition and is an important market for the company.

YEAST-BASED ASTAXANTHIN THE STRONGEST ANTIOXIDANT IN NATURE

  • For the first time, a flavorless & odorless astaxanthin product, with a competitive price
  • Enables market growth through expansion of Commercial sales in the USA & Canada
  • Profitable and efficientsupply chain

19

Market potential with user expansion

Current market (mainly soft-gels )

STATUS & POTENTIAL

Launched in the USA (2020)

By several dietary supplement companies including leading market brands

  • In launch and initial sales stages in a form of Gummies
  • Recently launched in a form of crude oil for use in Soft gels.

PATENTS AND REGULATION

FINANCIAL INFORMATION

\$31M Raised (2014-2021)

Market B2C 2021 Private Placement (December 2021): Raised \$8M TASE IPO (January 2021): Raised \$11M, Market cap of \$33M Former Equity Rounds (Private investments): Raised \$12M

Cash & Cash equivalents as of June 30, 2022: ~ \$8M The Cash will serve the company ongoing activities and

production increase from tens to hundreds of tons per year

Main Investors

Cider Holdings, Orgad, Arancia, Yitong Merage VC Phoenix-Excellence

FINANCIAL INFORMATION

thousands
in
USD
Q2/2022
YTD
Q2/2021
YTD
2021 2020
STATEMENT
OF
OPERATION
Net
Revenues
125 9
1
242 9
5
Market
Profit
Gross
(86) 5 2
3
1
9
B2C
2021
Operating
Loss
(3
384)
,
(2
156)
,
(4
467)
,
(3
056)
,
(*)
Adjusted
EBITDA
(3
021)
,
(1
947)
,
(4
113)
,
(2
635)
,
BALANCE
SHEET
Cash
cash
equivalents
and
Short
deposits
term
,
828
7
,
8
265
,
13
164
,
716
Working
Capital
5
842
,
5
686
,
10
151
,
(4
195)
,
Total
Assets
12
593
,
10
675
,
16
468
,
2
163
,
Share
Capital
8
406
,
6
180
,
11
674
,
(3
927)
,
CASH
FLOW
Cash
used
in
operating
activities
(4
010)
,
(2
088)
,
(3
823)
,
(2
976)
,
Cash
used
in
investing
activities
(1
085)
,
(1
304)
,
(1
259)
,
(77)
Cash
financing
used
in
activities
(109) 9
722
,
17
504
,
1
761
,

(*) Net profit excluding Interest, taxes, depreciation, amortization and share based compensation

NextFerm - Summary

Winning technology platform

Experienced team

Alternative proteinbooming market

Game changing

a vegan protein with neutral taste & animal like nutritional value

Leading value proposition in the global alternative protein market

THANK YOU!

For more information:

[email protected]

www.nextferm.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.